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Background. End-stage renal disease (ESRD) risk in patients with antineutrophil cytoplasmic antibody- (ANCA-) associated
glomerulonephritis (ANCA-GN) according to ANCA serotype and stratified by histological classification has not been
previously investigated. Methods. Patients from the Norwegian Kidney Biopsy Registry (NKBR) between 1991 and 2012 who
had biopsy-verified pauci-immune glomerulonephritis and positive antineutrophil cytoplasmic antibody serology were included.
Cases with ESRD during follow-up were identified in the Norwegian Renal Registry. ESRD-free survival with proteinase 3 (PR3)
versus myeloperoxidase- (MPO-) ANCA positivity stratified into 4 histological classes was investigated. Results. Three hundred
fifty-eight patients, of whom 87 progressed to ESRD during follow-up, were included. Patients with PR3- as compared to MPO-
ANCA were younger (58 versus 64 years, p = 0 001), had a higher percentage of males (62 versus 41%, p < 0 001), had a lower
percentage with a sclerozing glomerulonephritis pattern (4 versus 16%, p < 0 001), and had a significantly higher cumulative
ESRD-free survival (90 versus 80%, p = 0 007) at 1-year follow-up. No significant differences in cumulative ESRD-free survival
with PR3- as compared to MPO-ANCA were observed by histological stratification. Conclusion. Advanced glomerular sclerosis
is found more frequently in patients with MPO-ANCA, explaining the higher risk of ESRD. ANCA serotypes have no impact on
prognosis of patients with similar histological findings.
1. Introduction
Antineutrophil cytoplasmic antibody- (ANCA-) associated
vasculitis (AAV) typically affecting small vessels and kidney
involvement in the form of pauci-immune glomerulonephri-
tis (ANCA-GN) is common [1]. Even with modern treat-
ment, AAV is associated with significant morbidity and
mortality; moreover, in patients with ANCA-GN, progres-
sion to end-stage renal disease (ESRD) resulting in the need
for chronic dialysis treatment or kidney transplantation is a
particular concern [2]. Although ANCA-GN from a clinical
point of view usually is regarded as one disease, it is
associated with 2 different autoantibodies, proteinase 3
(PR3) and myeloperoxidase (MPO). A number of differences
between patients with PR3- as compared to MPO-AAV
have been described [3]. Differing genetic associations,
[4, 5] as well as substantial sex differences, have been
found [6, 7]. In some studies, worse baseline renal func-
tion in patients with MPO- as compared to PR3-ANCA-
GN has been reported [8, 9]. The histopathological
findings in ANCA-GN are qualitatively similar, irrespec-
tive of ANCA type [10, 11]. However, a few studies have
noticed quantitative differences in the form of a higher
percentage of normal glomeruli in PR3-ANCA-GN and
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more fibrotic changes in MPO-ANCA-GN [10, 12–14].
Despite a higher risk of relapse [15–17], renal prognosis
has often been found better in PR3- than in MPO-
AAGN [18–20]. However, it is unclear whether the poorer
prognoses associated with MPO- as compared to PR3-
ANCA-GN are caused by more advanced disease at base-
line [7, 8, 21–24] or due to differences in the nature of
inflammation associated with these 2 different autoanti-
body serotypes [25–27].
The histological classification of patients with ANCA-
GN into 4 groups, focal (≥50% normal glomeruli), crescen-
tic (≥50% cellular crescents), mixed (<50% normal, <50%
crescentic, and <50% globally sclerotic glomeruli), and scle-
rotic (≥50% globally sclerotic glomeruli), is useful for strat-
ifying patients according to the risk of progression to
ESRD [7, 20, 28–31]. To our knowledge, data comparing
renal disease and patient survival with PR3- as compared
to MPO-ANCA-GN, in cases with similar histological clas-
sification, have not been previously published. Here, using
data from the Norwegian Kidney Biopsy Registry, we have
compared baseline characteristics, histological findings,
and outcomes stratified for histological classification in
patients with ANCA-GN divided by PR3- as compared
to MPO-ANCA positivity.
2. Material and Methods
This study was approved by the Regional Committee for
Medical and Health Research Ethics. Data sources used are
based on informed consent.
In the present investigation, we included patients with
ANCA-GN from a previous study cohort used by our
group [29]. Identification of the study cohort, baseline
data, scoring of patients according to the histologic classi-
fication model of ANCA-GN, definition of observation
period, and endpoints were described in detail earlier
and only briefly reviewed here.
All patients with a biopsy containing at least 3 glomeruli
and histologically verified ANCA-GN in the Norwegian
Kidney Biopsy Registry (NKBR) from 1991 to 2012 were
included in the study cohort. The criteria for ANCA-GN
were the presence of pauci-immune necrotizing glomerulo-
nephritis and a positive ANCA titer. Baseline data, including
sex, age, ANCA serotype (determined by indirect immuno-
fluorescence and/or enzyme linked immunosorbent assay
methods), estimated glomerular filtration rate (eGFR), serum
albumin, systolic and diastolic blood pressure, and protein-
uria were obtained from the NKBR. An experienced renal
pathologist (LB) classified all cases according to the ANCA-
GN histological classification scheme. The observation
period was from the time of biopsy to the first event, ESRD,
death, or end of 2012. Furthermore, the observation period
was stratified according to the induction (≤1 year after
biopsy) and the remission (>1 year after biopsy) phases.
The primary endpoint of this study was ESRD, defined as
the initiation of chronic renal replacement therapy in the
form of dialysis or renal transplantation. Cases with ESRD
were identified by the linkage of the study cohort with the
Norwegian Renal Registry. The secondary endpoint was
death. These were identified by linking the study cohort with
the Population Registry of Norway and also used to define a
combined endpoint, which consists of patients with ESRD or
those who died during follow-up, whichever came first.
First, we analyzed baseline data stratified according to the
MPO-/PR3-ANCA serotype. Second, we analyzed 1- and 5-
year cumulative ESRD-free survival stratified for MPO and
PR3 positivity and specifically for each histological class of
ANCA-GN using Kaplan-Meier statistics. Finally, Cox
regression statistics was used to calculate the hazard ratio
(HR) of ESRD with MPO- versus PR3-ANCA after adjust-
ment for histological class, sex, and age. In these analyses,
deaths without ESRD were treated as censored events. The
analyses were then repeated using the secondary endpoints:
ESRD/death (deaths treated as an event) and deaths (deaths
with ESRD included as events). For significance testing,
Chi-square test was used with categorical variables, Mann–
Whitney U test for continuous variables, and Log-rank test
for comparisons of survival. SPSS, version 24 was used for
statistical analyses.
3. Results
Three hundred fifty-eight patients were identified and
included in the study cohort. One hundred ninety-three
(54%) were PR3-ANCA positive. One hundred eighty-seven
(52%) were male, and their mean age was 60 years
(SD=17), mean eGFR was 34ml/min/1.73m2 (SD=30),
and mean percentage glomeruli without crescents or global
sclerosis was 36% (SD=29). Other baseline characteristics
are shown in Table 1. Median observation period was 3.5
years (25th–75th percentiles = 0.6–7.7 years) and the total
number of patient years was 1716. During the short follow-
up period (≤1 year), 50 (14%) of the patients underwent
chronic renal replacement therapy and 47 (13%) patients
without ESRD died. Two hundred sixty-one (73%) patients
survived >1 year after the diagnosis of ANCA-GN without
ESRD, 37 (10%) later progressed to ESRD, 31 (9%) without
ESRD died, and 193 (54%) were alive without ESRD by the
end of 2012. Forty-eight of 87 patients with ESRD were alive
by the end of 2012.
Baseline data stratified according to ANCA serotype
are shown in Table 1. A significant sex difference was
observed. PR3-ANCA was found in 62% of male and
41% of female patients (p < 0 001). Mean age in patients
with PR3-ANCA was significantly lower (58 versus 64 years)
than that in patients with MPO-ANCA positivity (p = 0 001).
The “sclerotic” histological class was observed in 16% of the
patients with MPO-ANCA as compared to 4% with PR3-
ANCA (p < 0 001). No other significant differences in base-
line characteristics were observed, except for relatively
minor differences in serum albumin and diastolic blood
pressure. Median observation period with PR3-ANCA
was 3.9 years (25th–75th percentiles = 0.8–7.8 years) and
2.8 years (25th–75th percentiles = 0.4–7.3 years) with
MPO-ANCA. The total number of patient years was
1016 with PR3- and 701 with MPO-ANCA.
As demonstrated in Figure 1(a), cumulative survival
without ESRD (deaths without ESRD treated as a censoring
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event) in the 0-1-year observation period was significantly
better with PR3- rather than MPO-ANCA (p = 0 007). How-
ever, when the total observation period was analyzed, the dif-
ference was no longer statistically significant (p = 0 07,
Figure 1(b)). Furthermore, when cases with sclerotic histol-
ogy were excluded from the analysis, survival without ESRD
was basically similar in both ANCA subtypes (p = 0 34,
Figure 1(c)). One- and 5-year cumulative ESRD-free survival
rates with PR3- versus MPO-ANCA stratified according to
the histological classification model are shown in Table 2
and Figures 1(d)–1(g). No significant differences were
observed during the analysis of the survival rates stratified
for histological classification. In the Cox regression analysis,
HR for ESRD with MPO- versus PR3-ANCA was 1.30
(0.83–2.02, p = 0 25), with adjustments for age, gender, and
histological classification.
One- and 5-year cumulative ESRD-free survival
(deaths without ESRD treated as an event) with PR3- ver-
sus MPO-ANCA stratified according to the histological
classification model is shown in Table 3. No significant
differences were observed. In the Cox regression analysis,
HR for ESRD/death with MPO- versus PR3-ANCA was
1.04 (0.75–1.43, p = 0 83), with adjustments for age, sex,
and histological classification.
One- and 5-year cumulative patient survival (deaths with
ESRD included) with PR3- versus MPO-ANCA stratified
according to the histological classification model is shown
in Table 4. No significant differences were observed. In the
Cox regression analysis, HR for death with MPO- versus
PR3-ANCA was 0.77 (0.53–1.13, p = 0 18), with adjustment
for age, sex, and histological classification.
4. Discussion
In this study, we have demonstrated that the risk of ESRD
and/or death in patients with ANCA-GN is similar irrespec-
tive of PR3- or MPO-ANCA positivity when the histological
picture at baseline is similar. The consequence of this finding
for clinical practice and future research is that histological
classification is more relevant and important than serological
classification of ANCA-GN with respect to prognosis. To the
best of our knowledge, no study has previously reported
ANCA-serotype-specific outcomes of ANCA-GN, stratified
by histological classification. Explanation for this surprising
lack of data is probably that many studies involved small
samples unsuitable for stratified analyses [32]. We hope our
findings will encourage researchers to conduct multicenter
studies or meta-analyses that will confirm our results.
Our study confirms several previous findings with respect
to differences in baseline characteristics of patients with
ANCA-GN according to serotype [3]. In a number of studies,
the differences in male to female ratio in patients with PR3-
as compared to MPO-ANCA GN were identified [3, 6, 7].
A higher mean age in patients with MPO- than PR3-ANCA
was also previously described [3]. Similar to our findings,
sclerotic histology was significantly more frequent in patients
with MPO- than PR3-ANCA in a previous study with
patients recruited from Spain and the UK [33]. The probable
explanation is the fewer extrarenal symptoms and findings
and thus the increased delay in the diagnosis of ANCA-
GN in patients with MPO- than with PR3-ANCA. In
some studies, patients with MPO-ANCA had higher base-
line serum creatinine and a higher percentage of affected
glomeruli than those with PR3-ANCA [8–10, 12–14]. We
observed the same tendency in the current study. How-
ever, differences were not statistically significant. The
significantly higher risk of ESRD with MPO- as compared
to PR3-ANCA at 1 year of observation is also found in
numerous previous studies [3, 18–20]. Here, we can docu-
ment that this difference in prognosis is solely attributed
to a higher fraction with sclerotic histology among patients
with MPO- than PR3-ANCA.
The strength of this study is that it included a rela-
tively large population-based study cohort with reliable
registration of endpoints from high-quality national
registries. However, some limitations must also be consid-
ered. We know that the treatment regimen for ANCA-GN
in Norway during the study period almost exclusively
Table 1: Baseline characteristics in the total cohort and stratified for MPO- and PR3-ANCA.
Characteristic All, n = 358 MPO-ANCA, n = 165 PR3-ANCA, n = 193 p value
Males (%) 187 (52) 68 (41) 119 (62) <0.001
Mean age (SD) 60 (17) 64 (15) 58 (18) 0.001
eGFR (SD) 34 (30) 31 (28) 36 (32) 0.07
Serum albumin (SD) 32 (7) 32 (7) 31 (7) 0.04
Systolic blood pressure (SD) 142 (21) 144 (21) 141 (21) 0.08
Diastolic blood pressure (SD) 80 (11) 82 (11) 79 (11) 0.05
Proteinuria (SD) 1.8 (2.0) 1.9 (2.0) 1.7 (2.0) 0.25
Percentage normal glomeruli (SD) 36 (29) 33 (28) 38 (30) 0.07
Focal histology (%) 127 (35) 53 (32) 74 (38) 0.21
Mixed histology (%) 90 (25) 40 (25) 50 (26) 0.82
Crescentic histology (%) 106 (30) 45 (27) 61 (32) 0.32






















































































































consisted of cyclophosphamide and steroids, with azathio-
prine substituting for cyclophosphamide for maintenance
treatment after 2003 [19, 29, 34]. However, we do not know
the specific treatment plans of individual patients. In a previ-
ous study using the same patient cohort, we demonstrated
that outcomes were in line with those reported in other
studies, indicating that treatment followed acceptable inter-
national standards [29]. Another limitation is the lack of data
regarding extrarenal vasculitis manifestations. Such data are
not registered in the NKBR, which focuses on renal disease.
In conclusion, we have not found ANCA-serotype-
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Figure 1: (a) Kaplan-Meier plot demonstrating end-stage renal disease-free survival at 0-1 after diagnosis with MPO- versus PR3-ANCA. (b)
Kaplan-Meier plot demonstrating end-stage renal disease-free survival in total observation period withMPO- versus PR3-ANCA. (c) Kaplan-
Meier plot demonstrating end-stage renal disease-free survival in total observation period with MPO- versus PR3-ANCA. Cases with sclerotic
histology were excluded. (d) Kaplan-Meier plot demonstrating end-stage renal disease-free survival with MPO- versus PR3-ANCA in cases
with focal histology. (e) Kaplan-Meier plot demonstrating end-stage renal disease-free survival with MPO- versus PR3-ANCA in cases with
mixed histology. (f) Kaplan-Meier plot demonstrating end-stage renal disease-free survival with MPO- versus PR3-ANCA in cases with
crescentic histology. (g) Kaplan-Meier plot demonstrating end-stage renal disease-free survival with MPO- versus PR3-ANCA in cases
with sclerotic histology.
Table 2: End-stage renal disease-free survival at 1 and 5 years of follow-up with MPO- and PR3-ANCA, total cohort and stratified according
to histological classification.
Characteristic
N ESRD 1 year 5 years
p value
PR3-ANCA MPO-ANCA PR3-ANCA MPO-ANCA PR3-ANCA MPO-ANCA PR3-ANCA MPO-ANCA
All 193 165 41 46 90% 80% 78% 72% 0.07
Focal 74 53 8 4 96% 96% 89% 92% 0.67
Mixed 50 40 11 11 90% 84% 82% 69% 0.51
Crescentic 61 45 18 17 86% 72% 65% 69% 0.43
Sclerotic 8 27 4 14 75% 49% 50% 38% 0.35
Table 3: Overall and end-stage renal disease-free survival at 1 and 5 years of follow-up withMPO- and PR3-ANCA, total cohort and stratified
according to histological classification.
Characteristic
N ESRD/deaths 1 year 5 years
p value
PR3-ANCA MPO-ANCA PR3-ANCA MPO-ANCA PR3-ANCA MPO-ANCA PR3-ANCA MPO-ANCA
All 193 165 84 81 76% 69% 62% 55% 0.13
Focal 74 53 25 16 84% 87% 72% 71% 0.95
Mixed 50 40 19 19 80% 75% 73% 53% 0.53
Crescentic 61 45 36 27 64% 62% 43% 52% 0.92
Sclerotic 8 27 4 19 75% 37% 50% 30% 0.16
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histological classification. As a result, we conclude that with
respect to prognosis, histological classification is more
important than serologic classification in patients with
ANCA-GN.
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